CRISPR Gene-Editing Infusion Sustains LDL Cholesterol Reduction for One Year

A Phase 1 clinical trial at Cleveland Clinic demonstrated that a single CRISPR-Cas9 gene-editing infusion significantly lowered LDL cholesterol and triglycerides by approximately half in patients with lipid disorders resistant to standard treatments. These reductions were maintained for a full year, with the highest dose achieving a 52.5% decrease in LDL cholesterol. No serious adverse events were reported, marking a potential breakthrough for managing severe lipid conditions.